Micro‐to‐Nano Oncolytic Microbial System Shifts from Tumor Killing to Tumor Draining Lymph Nodes Remolding for Enhanced Immunotherapy
Advanced Materials · 2024-02 · 36 (7)
DOI: 10.1002/adma.202306488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 07.12.2023. Verfasst von Zhichao Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, General Project of Liaoning Provincial Department of Education.
Abstract (Originalsprache)
Because the tumor‐draining lymph nodes (TDLNs) microenvironment is commonly immunosuppressive, oncolytic microbe‐induced tumor antigens aren't sufficiently cross‐primed tumor specific T cells through antigen‐presenting cells (e.g., dendritic cells (DCs)) in TDLNs. Herein, this work develops the micro‐to‐nano oncolytic microbial therapeutics based on pyranose oxidase (P 2 O) overexpressed Escherichia coli (EcP) which are simultaneously encapsulated by PEGylated mannose and low‐concentrated photosensitizer nanoparticles (NPs). Following administration, P 2 O from this system generates toxic hydrogen peroxide for tumor regression and leads to the release of tumor antigens. The “microscale” EcP is triggered, following exposure to the laser irradiation, to secrete the “nanoscale” bacterial outer membrane vesicles (OMVs). The enhanced TDLNs delivery via OMVs significantly regulates the TDLNs immunomicroenvironment, promoting the maturation of DCs to potentiate tumor antigen‐specific T cells immune response. The micro‐to‐nano oncolytic microbe is leveraged to exert tumor killing and remold TDLNs for initiating potent activation of DCs, providing promising strategies to facilitate microbial cancer vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
- Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, China Medical University, Ministry of…
- Experimental Teaching Center, Faculty of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
ORCID-Profile: Jin Sun
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- General Project of Liaoning Provincial Department of Education
- Natural Science Foundation of Liaoning Province
- LiaoNing Revitalization Talents Program
- LiaoningProvince Applied BasicResearch Program
- National Key Research and Development Program of China
Zitieren
APA
Chen, Z., Liu, Y., Yu, Y., Yang, S., Feng, J., Zhu, Y., Huang, W., Qin, B., Guan, X., He, Z., Sun, M., & Sun, J. (2024). Micro‐to‐Nano Oncolytic Microbial System Shifts from Tumor Killing to Tumor Draining Lymph Nodes Remolding for Enhanced Immunotherapy. Advanced Materials, 36(7). https://doi.org/10.1002/adma.202306488
Vancouver
Chen Z, Liu Y, Yu Y, Yang S, Feng J, Zhu Y, et al. Micro‐to‐Nano Oncolytic Microbial System Shifts from Tumor Killing to Tumor Draining Lymph Nodes Remolding for Enhanced Immunotherapy. Advanced Materials. 2024;36(7). doi:10.1002/adma.202306488
BibTeX
@article{Chen2024,
author = {Chen, Zhichao and Liu, Yuhan and Yu, Yuxuan and Yang, Shihua and Feng, Jing and Zhu, Yinmei and Huang, Wanxu and Qin, Bin and Guan, Xinyao and He, Zhonggui and Sun, Mengchi and Sun, Jin},
title = {Micro‐to‐Nano Oncolytic Microbial System Shifts from Tumor Killing to Tumor Draining Lymph Nodes Remolding for Enhanced Immunotherapy},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {7},
doi = {10.1002/adma.202306488}
}
EUVIMED